Track topics on Twitter Track topics that are important to you
This is a single-blinded, one-treatment, combination dose escalation and pharmacokinetic study done in healthy volunteers. The investigators want to determine whether PTHrP(1-36) shares anabolic properties with the only currently approved anabolic agent, parathyroid hormone or PTH(1-34), which stimulates both osteoblastic bone resorption and formation. In a previous study done by the investigators, postmenopausal osteoporotic women on estrogen received 6.56 mcg/kg PTHrP(1-36) subcutaneously for three months daily. They experiences a 4.7% increase in bone mineral density (BMD) of the lumbar spine when compared with those taking placebo. They also displayed an increase in serum osteocalcin, a marker of bone formation, with no change in several markers of bone resorption. It is believed that the rapid absorption and clearance of PTHrP(1-36) likely plays a central role in its anabolic effect In order to further assess absorption, we are combining both pharmacokinetic and dose escalation methods for studying intravenous PTHrP given via a one-time bolus injection. The purpose is to define the maximum safe dose and measure the pharmacokinetic parameters of a single intravenous dose of Parathyroid Hormone-related Protein (1-36)[PTHrP(1-36)]. The results will be useful in determining future treatment options for osteoporosis.
Osteoporosis is a growing health problem. The most commonly used treatment options are anti-resorptive agents, which give a bone density increase of the lumbar spine in the 6-8% range over a 3-5 year period. A 100 % increase in bone mass would be needed to restore bone mass to peak, premenopausal levels. The ideal drug to treat osteoporosis would be a pure skeletal anabolic agent; however, the only currently approved anabolic agent, parathyroid hormone [PTH(1-34)] appears to only increase lumbar spine mass by 12-15% over a 2-3 year period when given alone.
Parathyroid hormone-related protein, [PTHrP(1-36)], is a peptide secreted by almost all normal tissues and cells that shares significant homology with PTH; and the investigators believe that it shares anabolic properties with PTH. In a previous study, PTHrP(1-36) administered subcutaneously to postmenopausal women for two weeks increased markers of bone formation (osteocalcin) while decreasing markers of osteoclastic bone resorption. In a subsequent study, postmenopausal osteoporotic women on estrogen received 6.56 mcg/kg PTHrP(1-36) subcutaneously for 3 months daily. They experienced a 4.7% increase in bone mineral density (BMD) of the lumbar spine compared to those taking placebo. The also displayed an increase in serum osteocalcin, a marker of bone formation, with no change in several markers of bone resorption. As a result of both rat and human research studies, the investigators feel the rapid absorption and clearance of PTHrP(1-36) likely plays a central role in its anabolic effect in humans.
In order to further assess the absorption of PTHrP, the investigators are doing this pharmacokinetic study using bolus intravenous PTHrP. It combines both pharmacokinetic and dose escalation methods for studying intravenous PTHrP given via a one-time bolus injection. Subcutaneous PTHrP has been shown to increase bone mass in previous studies done and would be the preferred route for administration of PTHrP in the treatment of osteoporosis. Comparing intravenous with subcutaneous PTHrP will yield much information about the bioavailability of PTHrP in vivo.
This six hour study has been designed to achieve the goals of (1) determining what is the maximum safe dose of PTHrP(1-36) that can be given intravenously as a one time bolus dose; and (2) what is the pharmacokinetic profile of a one-time intravenous bolus dose of PTHrP. A placebo group of 5 subjects will initially serve as a control. The investigators feel it is important to begin with very small amounts of intravenous PTHrP and gradually increase the dose for safety reasons. The initial single bolus intravenous dose to be tested is intentionally low (4 micrograms). Subsequent doses of PTHrP will be gradually increased using a standard dose escalation scale in groups of three subjects until a maximal dose of 400 mcg is reached or a dose limiting toxicity occurs at a dose lower than 400 mcg. The maximum determined safely tolerated dose will then be administered to a total of 10 normal healthy volunteers.
In all subjects at different dosing groups, frequent blood sampling within the first 20 minutes after IV administration of PTHrP will yield pharmacokinetic data about peak PTHrP blood levels and time to peak level T(max). After research subjects receive an intravenous bolus of PTHrP; blood samples will be collected for pharmacokinetic analysis of PTHrP at intervals of 2 minutes for the first 20 minutes, than at 25, 30, 45 and 60 minutes, then hourly for the next five hours. Measurement of calcium, creatinine, phosphorus, PTH, 1,25 Vitamin D and markers of bone metabolism will be obtained at baseline, and at hours one and three. After the baseline urine sample is obtained, urine will be collected at two hour intervals for calcium, creatinine, phosphorus, and markers of bone metabolism.
All subjects will be assigned in a single-blinded manner to receive either placebo or study drug. Initial subjects will be assigned to receive placebo or the starting dose of PTHrP: 4 micrograms. all groups of subjects will receive of PTHrP or placebo via intravenous bolus injection followed by a 3 ml normal saline solution flush over a 30-60 period. If subjects in the initial groups do not experience any adverse effects, doses of intravenous PTHrP will be increased in subsequent groups of three subjects each, and the doses for these groups will be 10, 40, 75, 150, 250 and lastly, 400 micrograms. 400 micrograms is the highest possible dose that will be given in this study. The dose that causes no dose-limiting toxicities will be given to a total of 10 healthy subjects. Data from this dosing group will be used to compare data from the investigator's previous pharmacokinetic and dose escalation studies, including recently completed a double-blind, crossover pharmacokinetic study comparing peak serum levels of PTH(1-34) and PTHrP(1-36) after a single subcutaneous injection. Preliminary results from that study indicated that PTHrP peaks earlier than PTH (6-15 minutes verses 45 minutes), despite the fact that the dose of PTHrP (~420 mcg) was 20 times greater than the dose of PTH (20 mcg).
This study will be performed in healthy young adults, ages 24-35 years. It is anticipated that we will need to screen 100 subjects to achieve a maximum of 52 evaluable subjects, to answer the questions posed by this study.
Allocation: Non-Randomized, Control: Placebo Control, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Parathyroid Hormone-related Protein
University of Pittsburgh Medical Center
University of Pittsburgh
Published on BioPortfolio: 2014-08-27T03:50:34-0400
This is a three month comparison trial of standard dose parathyroid Hormone (PTH (1-34) and two different doses of Parathyroid Hormone-related Protein (PTHrP). The investigators want to t...
PTH-related protein, or ''PTHrP'', is a hormone which was discovered in 1987. As its name implies, it is closely related to another hormone discovered in the 1920's named parathyroid horm...
Alendronate is a drug that blocks or reduces bone loss, while parathyroid hormone (PTH) stimulates the formation of new bone. The purpose of this study is to compare the bone-building effe...
This study looks at the effects of two medications, alendronate and parathyroid hormone, on bone mass and on bone formation and bone breakdown in women with osteoporosis. We will randomly ...
OBJECTIVES: I. Determine the effect of human parathyroid hormone (1-34) on bone mass in middle-aged men with idiopathic osteoporosis.
Intermittent parathyroid hormone (PTH) is the commonly used therapeutic approach for patients with severe osteoporosis. The goal of this study was to elucidate the effect of the intermittent PTH treat...
Parathyroid hormone PTH) levels are the main parameters to differentiate primary hyperparathyroidism (PHPT) from non-PTH-dependent hypercalcemia. We report a case of hypercalcemia with normal PTH leve...
It is known that high levels of parathyroid hormone-related protein (PTHrP) correlate with a bad prognostic in malignancies. Here we present a patient with advanced penile cancer (PC) without antecede...
In N = 400 women (46.9 ± 15.5 years), the prevalence of severe (
Recombinant parathyroid hormone (rPTH) increases bone mineral density (BMD). However, certain other potential effects of rPTH remain to be studied. The aim of this study is to identify whether bone tu...
A parathyroid hormone receptor subtype that recognizes both PARATHYROID HORMONE and PARATHYROID HORMONE-RELATED PROTEIN. It is a G-protein-coupled receptor that is expressed at high levels in BONE and in KIDNEY.
A ubiquitously expressed, secreted protein with bone resorption and renal calcium reabsorption activities that are similar to PARATHYROID HORMONE. It does not circulate in appreciable amounts in normal subjects, but rather exerts its biological actions locally. Overexpression of parathyroid hormone-related protein by tumor cells results in humoral calcemia of malignancy.
Cell surface proteins that bind PARATHYROID HORMONE with high affinity and trigger intracellular changes which influence the behavior of cells. Parathyroid hormone receptors on BONE; KIDNEY; and gastrointestinal cells mediate the hormone's role in calcium and phosphate homeostasis.
A parathyroid hormone receptor subtype found in the BRAIN and the PANCREAS. It is a G-protein-coupled receptor with a ligand specificity that varies between homologs from different species.
Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...